Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”


HHS - 21479 - State Pharmaceutical Assistance Transition Commission - Statutory (Congress Created)
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameState Pharmaceutical Assistance Transition CommissionAgency NameDepartment of Health and Human Services
Fiscal Year2005Committee Number21479
Original Establishment Date12/8/2003Committee StatusTerminated
Actual Termination Date1/19/2005Committee URLhttp://cms.hhs.gov/faca/spatc/details.asp
New Committee This FYNoPresidential Appointments*No
Terminated This FYYesMax Number of Members*23
Current Charter Date3/19/2004Designated Fed Officer Position Title*Health Insurance Specialist
Date Of Renewal Charter1/31/2005Designated Federal Officer PrefixMs.
Projected Termination Date1/31/2005Designated Federal Officer First Name*Marge
Exempt From Renewal*YesDesignated Federal Officer Middle Name
Specific Termination AuthoritySection 106 of MMA P.L. 108-173Designated Federal Officer Last Name*Watchorn
Establishment Authority*Statutory (Congress Created)Designated Federal Officer Suffix
Specific Establishment Authority*Section 106 of MMA P.L. 108-173Designated Federal Officer Phone*410-786-4361
Effective Date Of Authority*12/8/2003Designated Federal Officer Fax*
Exempt From EO 13875 Discretionary Cmte Designated Federal Officer Email*mwatchorn@cms.hhs.gov
Committee Type*Continuing
Presidential*No
Committee Function*Other Committee
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Terminate
Legislation to Terminate RequiredNo
Legislation StatusEnacted
How does cmte accomplish its purpose?*The committee will accomplish its purpose by addressing the unique transitional issues facing State pharmaceutical assistance programs and program participants due to the implementation of the voluntary prescription drug benefit program under Medicare part D.
How is membership balanced?*The State Pharmaceutical Assistance Transition Commission consists of the Secretary, or his designee and up to 70 members including the Chair. The panel membership includes a broad spectrum of industry professionals, which include:1) A representative of each Governor of each State that the Secretary identifies as operating on a statewide basis a State pharmaceutical assistance program that provides for eligibility and benefits comparable or more generous than the low-income assistance and eligibility and benefits offered under section 1860D-14 of the Social Security Act:2) Representatives from other States identified by the Secretary with other SPAP’s in operation 3) Representatives of organizations with an inherent interest in program participants or the program itself4) Representatives of Medicare Advantage organizations, pharmaceutical benefits managers and other private health insurance plans.
How frequent & relevant are cmte mtgs?*Meetings will be held once each calendar quarter, and will be called by the Chairperson.
Why advice can't be obtained elsewhere?*Section 106 of Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA)(P.L. 108-173)requires the Secretary of HHS to establish a State Pharmacy Assistance Transition Commission. The commission must submit to the President and the Congress a report that contains a detailed proposal (including specific legislative or administrative recommendations, if any) and other recommendations as the commission deems appropriate.
Why close or partially close meetings?Meetings are not closed. All meetings shall be open to the public except as determined otherwise by the Secretary or other official to whom the authority has been delegated. Notices of meetings are given to the public in the Federal Register, and there will be records of the meeting proceedings kept, as required by applicable laws and departmental regulations. In the event that a portion of a meeting is closed to the public, a report will be prepared that contains at a minimum a list of members and their business addresses, the Panel’s function, dates and places of meetings, and a summary of Panel activities and recommendations made during the fiscal year. A copy of the report will be provided to the Department Committee Management Officer.
Recommendation Remarks
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchNoAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentNA
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNAGrants Review CommentNA
Number Of Recommendations*0Access Contact Designated Fed. Officer*No
Number Of Recommendations CommentNAAccess Agency WebsiteNo
% of Recs Fully Implemented*0.00%Access Committee WebsiteNo
% of Recs Fully Implemented CommentNAAccess GSA FACA WebsiteNo
% of Recs Partially Implemented*0.00%Access PublicationsNo
% of Recs Partially Implemented CommentNAAccess OtherNo
Agency Feedback*Not ApplicableAccess CommentNA
Agency Feedback Comment*NANarrative Description*-commission terminated in January 2005
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$0.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$0.00Estimated Payments to Federal Staff*$0.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$256,960.00Est Travel Reimb Non-Fed Members nextFY*$256,960.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$0.00Est. Other Costs Next FY*$0.00
Total Costs$256,960.00Est. Total Next FY*$256,960.00
Date Cost Last Modified Est. Fed Staff Support Next FY*0.40
Federal Staff Support (FTE)*0.40Est Cost Remarks
Cost Remarks  
Hide Section - Interest Areas

Interest Areas

No interest areas selected for this committee.
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-014805State Pharmaceutical Assistance Transition Commission2004